INTCO MEDICAL(SZ:300677) Sou Hu Cai Jing·2025-09-16 13:49Core Viewpoint - The stock of Yingke Medical (300677) has shown a positive performance with a closing price of 37.05 yuan, reflecting a 1.51% increase on September 16, 2025, amidst varying capital flows from different investor groups [1][2]. Financial Performance - Yingke Medical reported a main revenue of 4.913 billion yuan for the first half of 2025, representing an 8.9% year-on-year increase [3]. - The net profit attributable to shareholders was 710 million yuan, up 21.02% year-on-year [3]. - The company's second-quarter revenue was 2.42 billion yuan, a 4.79% increase year-on-year, while the net profit for the same period was 358 million yuan, reflecting a 2.55% increase year-on-year [3]. - The company's gross profit margin stood at 24.23%, with a net profit margin of 14.79% [3]. Market Position - Yingke Medical's total market capitalization is 24.26 billion yuan, ranking 8th in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 17.07, significantly lower than the industry average of 69.34, indicating a potentially undervalued stock [3]. - The return on equity (ROE) is 4.03%, which is higher than the industry average of 1.8% [3]. Capital Flow Analysis - On September 16, 2025, the net inflow of main funds was 16.699 million yuan, accounting for 2.9% of the total transaction volume [1][2]. - Retail investors experienced a net outflow of 48.3817 million yuan, representing 8.39% of the total transaction volume [1][2]. - Over the past five days, the stock has seen fluctuations in capital flow, with significant net outflows from retail investors on multiple days [2]. Institutional Ratings - In the last 90 days, six institutions have given a buy rating for Yingke Medical, with an average target price of 33.24 yuan [4].